FDA Approved Drugs by Medical Condition

Search by medical condition for drugs approved by the Food and Drug Administration (FDA) for sale in the United States. Select the letter below that corresponds to the first letter of the medical condition you are searching for and all approved drugs classified under that category will be listed below.

*Healthy Patient Studies

Krintafel (tafenoquine) (by GlaxoSmithKline), Approved July 2018
For the prevention of malaria relapse in patients receiving appropriate antimalarial therapy

Acne

Avita Gel (by Penederm), Approved January 1997
Treatment for acne

Benzamycin (erythromycin 3%-benzoyl peroxide 5% topical gel) (by Dermik Laboratories), Approved November 2000
For the topical treatment of acne vulgaris

Clindamycin phosphate topical gel (by Target Research Associates), Approved November 2000
For once a day treatment of acne vulgaris

Clindamycin Phosphate Topical Solution USP 1% (by Morton Grove Pharmaceuticals), Approved July 1997
Generic equivalent of CLEOCIN Topical Solution 1%

Differin (adapalene gel) Gel, 0.1% (by Galderma Laboratories), Approved June 1996
Treatment for acne

Estrostep (norethindrone acetate and ethinyl estradiol) (by Pfizer), Approved July 2001
For the treatment of moderate acne vulgaris

Finevin (by Berlex Laboratories), Approved May 2001
Topical cream for the treatment of mild to moderate inflammatory acne vulgaris

Klaron (sodium sulfacet amide lotion ) Lotion, 10% (by Dermik Laboratories), Approved February 1997
Treatment for adult acne

Ortho Tri-Cyclen Tablets (norgestimate/ethinyl estradiol) (by Ortho-McNeil Pharmaceutical), Approved January 1997
Treatment for acne in women seeking contraception

Retin-A Micro (tretinoin gel) microsphere, 0.1% (by Advanced Polymer Systems), Approved February 1997
Treatment for acne

Seysara (sarecycline) (by Paratek Pharmaceuticals), Approved October 2018
For the treatment of moderate to severe acne vulgaris in patients 9 years of age and older.

Tazorac topical gel (by Allergan), Approved June 1997
Treatment for Psoriasis, Acne Vulgaris

Veltin (clindamycin phosphate and tretinoin) (by Stiefel), Approved July 2010
For the treatment of acne vulgaris

Acromegaly

Signifor LAR (pasireotide) (by Novartis), Approved December 2014
For the treatment of acromegaly

Acute Myelogenous Leukemia (AML)

Mylotarg (gemtuzumab ozogamicin) (by Wyeth), Approved May 2000
For the treatment of CD33 positive acute myeloid leukemia (AML)

Acute Myeloid Leukemia

Daurismo (glasdegib) (by Pfizer), Approved November 2018
For the treatment of newly-diagnosed acute myeloid leukemia in adults 75 years of age or older

IDHIFA (enasidenib) (by Celgene), Approved August 2017
For the treatment of relapsed or refractory acute myeloid leukemia with IDH2 mutation

Tibsovo (ivosidenib) (by Agios Pharmaceuticals), Approved July 2018
For the treatment of acute myeloid leukemia with a susceptible IDH1 mutation

Vyxeos (daunorubicin and cytarabine) (by Jazz Pharma), Approved August 2017
For the treatment of newly-diagnosed therapy-related AML or AML with myelodysplasia-related changes

Xospata (gilteritinib) (by Astellas), Approved November 2018
For the treatment of acute myeloid leukemia with a FLT3 mutation

Acute Pain

Belbuca (buprenorphine) (by Endo Pharmaceuticals), Approved October 2015
For the management of severe pain

Dsuvia (sufentanil) (by AcelRx Pharma), Approved November 2018
For the management of acute pain

Exparel (bupivacaine liposome injectable suspension) (by Pacira Pharmaceuticals), Approved November 2011
For postsurgical analgesia

Omidria (phenylephrine and ketorolac injection) (by Omeros), Approved June 2014
For use during eye surgery to prevent intraoperative miosis and reduce post-operative pain

Tivorbex (indomethacin) (by Iroko Pharmaceuticals), Approved February of 2014
For the treatment of acute pain

Troxyca ER (oxycodone + naltrexone) (by Pfizer), Approved August 2016
For the management of severe pain

Vivlodex (meloxicam) (by Iroko Pharmaceuticals), Approved October 2015
For the management of osteoarthritis pain

Xartemis XR (oxycodone hydrochloride and acetaminophen) extended release (by Mallinckrodt Pharmaceuticals), Approved March 2014
For the management of acute pain

Zingo (lidocaine hydrochloride monohydrate) (by Powder Pharmaceuticals), Approved August 2007
For local analgesia prior to venipuncture or peripheral intravenous cannulation

Addictions

Bunavail (buprenorphine and naloxone) (by BioDelivery Sciences), Approved June 2014
For the maintenance treatment of opioid dependence

Lucemyra (lofexidine) (by US Worldmeds), Approved May 2018
For the mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults

Vivitrol (naltrexone for extended-release injectable suspension) (by Alkermes), Approved October 2010
For the prevention of relapse to opioid dependence

Zubsolv (buprenorphine and naloxone) (by Orexo AB), Approved July 2013
For the maintenance treatment of opioid dependence

Adenocarcinoma

Keytruda (pembrolizumab) (by Merck), Approved September 2017
For the treatment of PD-L1 expressing gastric or gastroesophageal junction adenocarcinoma

Adverse Effects, Drugs

Actemra (tocilizumab) injection (by Genentech), Approved September 2017
For the treatment of CAR T cell-induced severe or life-threatening cytokine release syndrome

Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo) (by Portola Pharmaceuticals), Approved May 2018
for the reversal of factor Xa inhibitors

Bunavail (buprenorphine and naloxone) (by BioDelivery Sciences), Approved June 2014
For the maintenance treatment of opioid dependence

Kcentra (Prothrombin Complex Concentrate) (by CSL Behring), Approved May 2013
For the reversal of vitamin K antagonist therapy-induced coagulation factor deficiency

Movantik (naloxegol) (by AstraZeneca), Approved September 2014
For the treatment of opiod-induced constipation in adults with chronic non-cancer pain

Myalept (metreleptin for injection) (by Bristol-Myers Squibb), Approved February of 2014
For the treatment of congenital or acquired generalized lipodystrophy

Neutroval (tbo-filgrastim) (by Teva Pharmaceutical), Approved August 2012
For the reduction in the duration of severe chemotherapy-induced neutropenia

Praxbind (idarucizumab) (by Boehringer Ingelheim), Approved October 2015
For the reversal of the anticoagulant effects of dabigatran

Sustol (granisetron) (by Heron Therapeutics), Approved August 2016
For the prevention of chemotherapy-induced nausea and vomiting

Symproic (naldemedine) (by Shionogi), Approved March 2017
For the treatment of opioid-induced constipation

Vistogard (uridine triacetate) (by Wellstat Therapeutics), Approved December 2015
For the emergency treatment of patients with a fluorouracil or capecitabine overdose

Voraxaze (glucarpidase) (by BTG International), Approved January 2012
For the treatment of toxic plasma methotrexate concentrations in patients with impaired renal function

AIDS and AIDS related infections

Clarithromycin (Biaxin) (by Abbott Laboratories), Approved December 1995
Treatment for the prevention of disseminated Mycobacterium avium complex (MAC)

Syndros (dronabinol oral solution) (by Insys Therapeutics), Approved July 2016
For the treatment of anorexia associated with AIDS and nausea and vomiting associated with cancer chemotherapy

Valcyte (valganciclovir HCl) (by Roche), Approved March 2001
For the treatment of cytomegalovirus retinitis in patients with AIDS

Alcohol Dependence

Campral (acamprosate calcium) (by Forest Laboratories), Approved August, 2004
For the treatment of alcohol dependence and the maintenance of alcohol abstinence

Naltrexone Hydrochloride Tablets (by Barr Laboratories), Approved May 1998
Generic equivalent of Revia

Vivitrol (naltrexone for extended-release injectable suspension) (by Alkermes), Approved April 2006
For the treatment of alcohol dependence

Allergies & Asthma

Dymista (azelastine hydrochloride and fluticasone propionate) (by Meda Pharmaceuticals Inc), Approved May 2012
For the relief of symptoms of seasonal allergic rhinitis

Grastek (Timothy Grass Pollen Allergen Extract) (by Merck), Approved April 2014
For the treatment of grass pollen-induced allergic rhinitis

Oralair (Sweet Vernal, Orchard, Perennial Rye, Timothy and Kentucky Blue Grass Mixed Pollens Allergen Extract) (by Greer Labs), Approved April 2014
For the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis

Qnasl (beclomethasone dipropionate) nasal aerosol (by Teva Pharmaceutical), Approved March 2012
For the treatment of seasonal and perennial allergic rhinitis

Ragwitek (Short Ragweed Pollen Allergen Extract) (by Merck), Approved April 2014
For the treatment of short ragweed pollen-induced allergic rhinitis

Allergy

AK-Con-A (naphazoline ophthalmic) (by Akorn), Approved January 1996
Over-the-counter combination vasoconstrictor/antihistamine product for opthalmic use

Allegra (fexofenadine hydrochloride) (by Hoechst Marion Roussel), Approved July 1996
Treatment for seasonal allergy symptoms

Allegra-D (by Hoechst Marion Roussel), Approved March 1998
Treatment for nasal congestion due to seasonal allergy

Astelin nasal spray (by Wallace Laboratories), Approved November 1996
Treatment for seasonal allergic rhinitis

Astepro (azelastine hydrochloride nasal spray) (by Meda Pharmaceuticals Inc), Approved October 2008
For the treatment of seasonal and perennial allergic rhinitis

Atrovent (ipratropium bromide) (by Boehringer Ingelheim), Approved January 1996
Treatment for runny nose due to allergies and the common cold

Clarinex (by Schering-Plough), Approved February 2002
Once-daily oral tablet for the treatment of allergic rhinitis and chronic ideopathic urticaria

Claritin RediTabs (10 mg loratadine rapidly-disintegrating tablet) (by Schering-Plough), Approved January 1997
Treatment for seasonal allergy symptoms

Clemastine fumarate syrup (by Morton Grove Pharmaceuticals), Approved March 1998
Generic equivalent of Tavist Syrup

Dymista (azelastine hydrochloride and fluticasone propionate) (by Meda Pharmaceuticals Inc), Approved May 2012
For the relief of symptoms of seasonal allergic rhinitis

Flonase Nasal Spray (by GlaxoSmithKline), Approved November 1997
Treatment for seasonal and perennial allergic rhinitis

Grastek (Timothy Grass Pollen Allergen Extract) (by Merck), Approved April 2014
For the treatment of grass pollen-induced allergic rhinitis

IvyBlock (by EnviroDerm Pharmaceuticals), Approved September 1996
Treatment for poison ivy, poison oak, and poison sumac

Nasacort AQ (triamcinolone acetonide) Nasal Spray (by Rhone Poulenc Rorer), Approved May 1996
Treatment for allergic rhinitis

NasalCrom Nasal Spray (by Pharmacia & Upjohn), Approved April 2001
Over-the-counter nasal spray for treatment of all nasal allergy symptoms

Nasonex Nasal Spray (by Schering-Plough), Approved January 1999
Treatment of seasonal allergic rhinitis

Oralair (Sweet Vernal, Orchard, Perennial Rye, Timothy and Kentucky Blue Grass Mixed Pollens Allergen Extract) (by Greer Labs), Approved April 2014
For the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis

Patanase (olopatadine hydrochloride) (by Alcon), Approved April 2008
For the treatment of seasonal allergic rhinitis

Qnasl (beclomethasone dipropionate) nasal aerosol (by Teva Pharmaceutical), Approved March 2012
For the treatment of seasonal and perennial allergic rhinitis

Ragwitek (Short Ragweed Pollen Allergen Extract) (by Merck), Approved April 2014
For the treatment of short ragweed pollen-induced allergic rhinitis

Rhinocort Aqua Nasal Spray (by AstraZeneca), Approved October 1999
A nasal spray containing budesonide

Tavist (clemastine fumarate) (by Novartis), Approved March 2001
Oral tablet for temporary relief of symptoms associated with hay fever, allergic rhinitis, and the common cold

Tri-Nasal Spray (triamcinolone acetonide spray) (by Muro Pharmaceutical), Approved February 2000
For treatment of nasal symptoms of allergic rhinitis in adults and children age 12 or older

Vancenase AQ 84 mcg Double Strength (by Schering-Plough), Approved June 1996
Treatment for allergic and non-allergic rhinitis

Veramyst (fluticasone furoate) (by GlaxoSmithKline), Approved April 2007
For the treatment of seasonal and perennial allergic rhinitis

Xyzal (levocetirizine dihydrochloride) (by UCB), Approved May 2007
For the treatment of seasonal and perennial allergic rhinitis and urticaria

Zerviate (cetirizine ophthalmic solution 0.24%) (by NicOx), Approved May 2017
For the treatment of ocular itching associated with allergic conjunctivitis

Zyrtec (cetirizine HCl) (by Pfizer), Approved December 1995
Treatment for year-round allergies, seasonal allergic rhinitis, and chronic itching and hives

Allergy (Pediatric)

Claritin Syrup (loratadine) (by Schering-Plough), Approved October 1996
Treatment for children with seasonal allergies

Qnasl (beclomethasone dipropionate) nasal aerosol (by Teva Pharmaceutical), Approved March 2012
For the treatment of seasonal and perennial allergic rhinitis

Alzheimer's Disease

ARICEPT (donepezil hydrochloride) (by Eisai), Approved December 1996
Treatment for Alzheimer's Disease

Exelon (rivastigmine tartrate) (by Novartis), Approved April 2000
Indicated for the treatment of mild to moderate dementia of the Alzheimer's type

Exelon (rivastigmine tartrate) (by Novartis), Approved July 2007
For the treatment of Alzheimer's and Parkinson's disease-related dementia

Femstat 3 (butoconazole nitrate 2%) (by Procter & Gamble, Roche), Approved December 1995
Over the counter treatment for vaginal yeast infections

Namenda (memantine HCl) (by Forest Laboratories), Approved October 2003
For the treatment of moderate to severe dementia of the Alzheimer’s type.

Namzaric (memantine hydrochloride extended-release + donepezil hydrochloride) (by Forest Laboratories), Approved December 2014
For the treatment of moderate to severe dementia of the Alzheimer's type

Reminyl (galantamine hydrobromide) (by Janssen Pharmaceuticals), Approved February 2001
For the treatment of mild to moderate dementia of the Alzheimer's type

Amenorrhea

Prometrium (by Solvay Pharmaceuticals), Approved May 1998
Treatment for amenorrhea (abnormal cessation of menses)

Amyloidosis

Onpattro (patisiran) (by Alnylam Pharmaceuticals), Approved August 2018
For the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults

Tegsedi (inotersen) (by Ionis Pharmaceuticals), Approved October 2018
For the treatment of the polyneuropathy of hereditary transthyretinmediated amyloidosis in adults

Amyotrophic Lateral Sclerosis (ALS)

Radicava (edaravone) (by Mitsubishi Tanabe Pharma), Approved May 2017
For the treatment of amyotrophic lateral sclerosis

Rilutek (riluzole) (by Rhone Poulenc Rorer), Approved December 1995
Treatment for amyotrophic lateral sclerosis (ALS)

Anal Fissures

Rectiv (nitroglycerin) ointment 0.4% (by ProStrakan), Approved June 2011
For the treatment of chronic anal fissure

Anemia

Cablivi (caplacizumab-yhdp) (by Ablynx), Approved February 2019
For the treatment of acquired thrombotic thrombocytopenic purpura

Elelyso (taliglucerase alfa) (by Pfizer), Approved May 2012
For the treatment of Gaucher disease

Ferriprox (deferiprone) (by Apotex), Approved October 2011
For the treatment of transfusional iron overload due to thalassemia

Injectafer (ferric carboxymaltose injection) (by Luitpold Pharmaceuticals), Approved July 2013
For the treatment of iron deficiency anemia

Omontys (peginesatide) (by Affymax), Approved March 2012
For the treatment of anemia due to chronic kidney disease

Venofer (iron sucrose injection) (by Luitpold Pharmaceuticals), Approved November 2000
For the treatment of iron deficiency anemia in patients undergoing chronic hemodialysis

Anesthesia (Local)

Zingo (lidocaine hydrochloride monohydrate) (by Powder Pharmaceuticals), Approved August 2007
For local analgesia prior to venipuncture or peripheral intravenous cannulation

Angina

Caduet (amlodipine/atorvastatin) (by Pfizer), Approved January 2004
For the treatment of hypertension, chronic stable angina and vasospastic angina

Nitrostat (nitroglycerin) Tablets (by Parke-Davis), Approved May 2000
For the acute relief of an attack or acute prophylaxis of angina pectoris due to coronary artery disease.

Posicor (by Roche), Approved June 1997
Treatment for hypertension and chronic stable angina pectoris

Ranexa (ranolazine) (by CV Therapeutics), Approved January 2006
For the treatment of chronic angina in patients failing first-line therapy

Tiazac (diltiazem hydrochloride) (by Forest Laboratories), Approved February 1998
Treatment for chronic stable angina

Toprol-XL (metoprolol succinate) (by AstraZeneca), Approved January 1995
For the treatment of hypertension, angina pectoris and heart failure

Ankylosing Spondylitis

Cimzia (certolizumab pegol) (by UCB), October 2013
For the treatment of active ankylosing spondylitis

Rayos (prednisone) delayed-release tablets (by Horizon Pharma), Approved July of 2012
For the treatment of certain inflammatory diseases, including arthritis, COPD, asthma and psoriatic conditions

Anorexia

Syndros (dronabinol oral solution) (by Insys Therapeutics), Approved July 2016
For the treatment of anorexia associated with AIDS and nausea and vomiting associated with cancer chemotherapy

Arrhythmia

Procanbid (procainamide hydrochloride extended-release tablets) (by Warner-Lambert), Approved January 1996
Treatment for ventricular arrhythmias

Arthritis and Arthritic Pain

Arthrotec (by Searle), Approved December 1997
Treatment for arthritis

Cimzia (certolizumab pegol) (by UCB), Approved September 2013
For the treatment of active psoriatic arthritis

Lodine XL (etodolac) (by Wyeth), Approved February 1998
Treatment for arthritis

Otezla (apremilast) (by Celgene), Approved March 2014
For the treatment of adults with active psoriatic arthritis

Rayos (prednisone) delayed-release tablets (by Horizon Pharma), Approved July of 2012
For the treatment of certain inflammatory diseases, including arthritis, COPD, asthma and psoriatic conditions

Tolmetin Sodium (by Teva Pharmaceutical), Approved March 1997
Treatment for arthritis

Xeljanz (tofacitinib) (by Pfizer), Approved November 2012
For the treatment of moderately to severely active rheumatoid arthritis

Zilretta (triamcinolone acetonide extended-release injectable suspension) (by Flexion Therapeutics), Approved October 2017
For the treatment of osteoarthritis knee pain

Arthritis and Arthritic Pain (Pediatric)

Actemra (ocilizumab) (by Genentech), Approved May 2013
For the treatment of Polyarticular Juvenile Idiopathic Arthritis

Actemra (tocilizumab) (by Genentech), Approved April 2011
For the treatment of systemic juvenile idiopathic arthritis

Aspergillosis

Cresemba (isavuconazonium sulfate) (by Astellas), Approved March 2015
For the treatment of invasive aspergillosis and invasive mucormycosis

Asthma

Accolate (by AstraZeneca), Approved October 1996
Treatment for asthma

Advair (fluticasone propionate and salmeterol) (by GlaxoSmithKline), Approved August 2000
For the treatment of asthma and chronic obstructive pulmonary disease

Alvesco (ciclesonide) (by Nycomed), Approved January 2008
For the maintenance treatment of asthma as prophylactic therapy in adults and adolescents

Arnuity Ellipta (fluticasone furoate inhalation powder) (by GlaxoSmithKline), Approved August 2014
For the treatment of asthma

Azmacort (triamcinolone acetonide) Inhalation Aerosol (by Rhone Poulenc Rorer), Approved November 1996
Treatment for asthma

Cinqair (reslizumab) (by Teva Pharmaceuticals), Approved March 2016
For the treatment of severe asthma

Dulera (mometasone furoate + formoterol fumarate dihydrate) (by Merck), Approved June 2010
For the treatment of asthma

Dupixent (dupilumab) (by Regeneron Pharmaceuticals), Approved October 2018
For the treatment of moderate-to-severe asthma

Flovent Rotadisk (by GlaxoSmithKline), Approved November 1997
Treatment of asthma in patients four and older

Foradil Aerolizer (formoterol fumarate inhalation powder) (by Novartis), Approved February 2001 (asthma, bronchospasm); September 2001 (COPD)
Bronchodilator for COPD, asthma and bronchospasm

Metaprotereol Sulfate Inhalation Solution, 5% (by Morton Grove Pharmaceuticals), Approved March 1997
Generic equivalent of Alupentr Inhalation Solution, 5%

Nucala (mepolizumab) (by GlaxoSmithKline), Approved November 2015
For the treatment of severe asthma with an eosinophilic phenotype

Qvar (beclomethasone dipropionate) (by Ivax), Approved May 2002
For the treatment of asthma

Rayos (prednisone) delayed-release tablets (by Horizon Pharma), Approved July of 2012
For the treatment of certain inflammatory diseases, including arthritis, COPD, asthma and psoriatic conditions

Serevent (by GlaxoSmithKline), Approved September 1997
Treatment of asthma

Singulair (by Merck), Approved February 1998
Treatment for asthma

Tilade (nedocromil sodium) (by Rhone Poulenc Rorer), Approved April 1997
Treatment for asthma

Tilade (nedocromil sodium) (by Rhone Poulenc Rorer), Approved November 1997
Treatment for mild to moderate asthma

Vanceril 84 mcg Double Strength (beclomethasone dipropionate, 84 mcg) Inhalation Aerosol (by Schering-Plough), Approved January 1997
Treatment for asthma

Ventolin HFA (albuterol sulfate inhalation aerosol) (by GlaxoSmithKline), Approved April 2001
For the treatment or prevention of bronchospasm

Xolair (omalizumab) (by Genentech), Approved June 2003
For the treatment of asthma

Zyflo (Zileuton) (by Abbott Laboratories), Approved January 1997
Treatment for asthma in patients 12 years and older

Asthma (Pediatric)

Accolate (by AstraZeneca), Approved September 1999
zafirlukast, 10 mg and 20 mg tablets.

Arnuity Ellipta (fluticasone furoate inhalation powder) (by GlaxoSmithKline), Approved August 2014
For the treatment of asthma

Dupixent (dupilumab) (by Regeneron Pharmaceuticals), Approved October 2018
For the treatment of moderate-to-severe asthma

Tilade (nedocromil sodium) (by Rhone Poulenc Rorer), Approved April 1997
Treatment for mild-to-moderate bronchial asthma

Atherosclerosis

Lescol (fluvastatin sodium) (by Novartis), Approved September 1997
Treatment for coronary atherosclerosis

Plavix (clopidogrel bisulfate) (by Sanofi-aventis, Bristol-Myers Squibb), Approved November 1997
Treatment for cardiac atherosclerotic events

Praluent (alirocumab) (by Sanofi Aventis), Approved July 2015
For the treatment of heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease

Athlete's Foot (Tinea Pedis)

Lamisil (terbinafine hydrochloride) Solution, 1% (by Novartis), Approved March 2000
For the treatment of athlete's foot, jock itch and ringworm

Lotrisone (clotrimazole/betamethasone diproprionate) lotion (by Schering-Plough), Approved December 2000
For the topical treatment of symptomatic inflammatory tinea pedis, tinea cruris, and tinea corporis

Mentax (1% butenafine HCl cream) (by Penederm), Approved December 1997
Treatment for athlete's foot

Atopic Dermatitis

Desonate (desonide) (by Dow Pharm), Approved October 2006
For the treatment of atopic dermatitis

Dupixent (dupilumab) (by Regeneron Pharmaceuticals), Approved March 2017
For the treatment of atopic dermatitis

Elidel (by Novartis), Approved December 2001
Topical cream for the treatment of atopic dermatitis

Eucrisa (crisaborole) ointment (by Pfizer), Approved December 2016
For the treatment of atopic dermatitis

Protopic (tacrolimus) ointment (by Fujisawa Healthcare), Approved December 2000
For short-term and intermittent long-term treatment of moderate to severe atopic dermatitis

Verdeso (desonide) (by Connetics Corporation), Approved September 2006
For the treatment of atopic dermatitis

Atrial Fibrillation

Cardizem (R) (Diltiazem HC1 for injection) Monvial (R) (by Hoechst Marion Roussel), Approved September 1997
Delivery system for Monovial

Corvert Injection (ibutilide fumarate injection) (by Pharmacia & Upjohn), Approved December 1995
Treatment for irregular contractions of the heart

Eliquis (apixaban) (by Bristol-Myers Squibb), Approved December 2012
For the prevention of stroke and systemic embolism resulting from nonvalvular atrial fibrillation

Multaq (dronedarone) (by Sanofi-aventis), Approved July 2009
For the treatment of paroxysmal or persistent atrial fibrillation or atrial flutter

Pradaxa (dabigatran etexilate mesylate) (by Boehringer Ingelheim), Approved October 2010
For the risk reduction of stroke and embolism due to atrial fibrillation

Rythmol (by Knoll Pharmaceutical), Approved January 1998
Treatment for paroxysmal atrial fibrillation

Savaysa (edoxaban) (by Daiichi Sankyo), Approved January 2015
For the treatment of deep vein thrombosis, pulmonary embolism and risk of stroke and embolism due to atrial fibrillation

Tikosyn Capsules (by Pfizer), Approved October 1999
Capsules of dofetilide

Xarelto (rivaroxaban) (by Bayer), Approved July 2011
For the prophylaxis of deep vein thrombosis during knee or hip replacement surgery

Xarelto (rivaroxaban) (by Janssen Pharmaceuticals), Approved November 2011
For the reduction in the risk of stroke and systemic embolism resulting from atrial fibrillation

Attention Deficit/Hyperactivity Disorder (ADHD - Adults)

Quillivant XR (methylphenidate hydrochloride) (by NextWave Pharmaceuticals), Approved September 2012
For the treatment of Attention Deficit Hyperactivity Disorder

Attention Deficit/Hyperactivity Disorder (ADHD - Pediatric)

Adderall (mixed salts of a single-entity amphetamine) (by Richwood Pharmaceutical), Supplemental NDA Approved February 1996
Treatment for attention-deficit/hyperactivity disorder

Adderall XR (by Shire Pharmaceuticals), Approved October 2001
Once-daily medication for the treatment of attention deficit/hyperactivity disorder (ADHD)

Concerta (by Alza), Approved August 2000
For the treatment of Attention Deficit Hyperactivity Disorder

Focalin (dexmethylphenidate HCl) (by Celgene), Approved November 2001
For the treatment of attention deficit hyperactivity disorder (ADHD)

Intuniv (guanfacine extended-release) (by Shire Pharmaceuticals), Approved September 2009
For the treatment of ADHD in children and adolescents

Kapvay (clonidine hydrochloride) (by Shionogi), Approved October 2010
For the treatment of attention deficit hyperactivity disorder

Metadate CD (by Celltech Pharmaceuticals), Approved April 2001
Oral capsules for the treatment of attention deficit hyperactivity disorder

Ritalin LA (methylphenidate HCl) (by Novartis), Approved June 2002
Oral capsules for the treatment Attention-Deficit/Hyperactivity Disorder (ADHD)

Strattera (atomoxetine HCl) (by Eli Lilly), December 2002
For the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children, adolescents and adults.

Vyvanse (Lisdexamfetamine Dimesylate) (by New River), Approved February 2007
For the treatment of Attention-Deficit/Hyperactivity Disorder

Bacterial Infections

Abthrax (raxibacumab) (by GlaxoSmithKline), Approved December of 2012
For the treatment and prevention of anthrax

Aemcolo (rifamycin) (by Aries Pharmaceuticals), Approved November 2018
For the treatment of traveler's diarrhea

Anthim (obiltoxaximab) (by Elusys Therapeutics), Approved March 2016
For the treatment of inhalational anthrax

Avycaz (ceftazidime-avibactam) (by Actavis), Approved February 2015
For the treatment of complicated intra-abdominal and urinary tract infections

Baxdela (delafloxacin) tablets and injection (by Melinta Therapeutics), Approved June 2017
For the treatment of acute bacterial skin and skin structure infections

Cefazolin and Dextrose USP (by B Braun Medical), Approved July 2000
Respiratory tract infections

Dalvance (dalbavancin) (by Durata Therapeutics), Approved May 2014
For the treatment of acute bacterial skin and skin structure infections

Invanz (by Merck), Approved November 2001
Once-daily injectable treatment for bacterial infections

Metronidazole 1.3% Vaginal Gel (by Actavis, Inc.), Approved April 2014
For the treatment of bacterial vaginosis

Nuzyra (omadacycline) (by Paratek Pharmaceuticals), Approved October 2018
For the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections

Omnicef (by Warner-Lambert), Approved December 1997
Treatment against various bacterias

Orbactiv (oritavancin) (by The Medicines Company), Approved August 2014
For the treatment of acute bacterial skin and skin structure infections

Sirturo (bedaquiline) (by Janssen Therapeutics), Approved December 2012
For the treatment of multi-drug resistant tuberculosis

Sivextro (tedizolid phosphate) (by Cubist Pharmaceuticals), Approved June 2014
For the treatment of acute bacterial skin and skin structure infections

Solosec (secnidazole) (by Symbiomix Therapeutics), Approved September 2017
For the treatment of bacterial vaginosis

Spectracef (by TAP Pharmaceuticals), Approved August 2001
Oral tablets for the treatment of mild to moderate bacterial infections

Synercid I.V. (by Rhone Poulenc Rorer), Approved September 1999
quinupristin and dalfopristin for injection

Teflaro (ceftaroline fosamil) (by Cerexa), November 2010
For the treatment of bacterial skin infections and bacterial pneumonia

Trovan (by Pfizer), Approved December 1997
Treatment for bacterial infections

Vaxchora (Cholera Vaccine, Live, Oral) (by PaxVax), Approved June 2016
For active immunization against Cholera

Vibativ (telavancin) (by Theravance), Approved June 2013
For the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by staph aureus

Vibativ (telavancin) (by Theravance), Approved September 2009
For the treatment of complicated skin and skin structure infections

Xerava (eravacycline) (by Tetraphase Pharmaceuticals), Approved August 2018
For the treatment of complicated intra-abdominal infections

Zemdri (plazomicin) (by Achaogen), Approved June 2018
For the treatment of complicated urinary tract infections

Zerbaxa (ceftolozane + tazobactam) (by Cubist Pharmaceuticals), Approved December 2014
For the treatment of complicated intra-abdominal and urinary tract infections

Zinplava (bezlotoxumab) (by Merck), Approved October 2016
For the treatment of recurrent Clostridium difficile infection in patients receiving antibacterial treatment

Batten Disease

Brineura (cerliponase alfa) (by BioMarin), Approved April 2017
For the treatment of late infantile neuronal ceroid lipofuscinosis type 2

Benign Prostatic Hyperplasia (Enlarged Prostate)

Dutasteride (by GlaxoSmithKline), Approved November 2001
For the treatment of symptomatic benign prostatic hyperplasia

FLOMAX (by Boehringer Ingelheim), Approved October 1997
Treatment for benign prostatic hypertrophy (BPH)

Jalyn (dutasteride + tamsulosin) (by GlaxoSmithKline), Approved June 2010
For the treatment of benign prostatic hyperplasia

UroXatral (alfuzosin HCl extended-release tablets) (by Sanofi-aventis), Approved June 2003
For the treatment of of the signs and symptoms of benign prostatic hyperplasia

Bipolar Disorder

Saphris (asenapine) (by Schering-Plough), Approved August of 2009
For the treatment of schizophrenia and manic or mixed bipolar 1 episodes

Stavzor (valproic acid delayed release) (by Banner Pharmacaps), Approved July 2008
For the treatment of bipolar manic disorder, seizures and migraine headaches

Vraylar (cariprazine) (by Allergan), Approved September 2015
For the treatment of schizophrenia and bipolar disorder

Bladder Cancer

Keytruda (pembrolizumab) (by Merck), Approved May 2017
For the treatment of urothelial carcinoma (bladder cancer)

Tecentriq (atezolizumab) (by Genentech), Approved May 2016
For the treatment of urothelial carcinoma and metastatic non-small cell lung cancer

Bladder Carcinoma

Imfinzi (durvalumab) (by AstraZeneca), Initially approved May 2017
For the treatment of advanced or metastatic urothelial carcinoma and Stage III non-small cell lung cancer

Bladder Disorders

Detrol (tolterodine tartrate) (by Pharmacia & Upjohn), Approved March 1998
Treatment for an overactive bladder

Detrol LA (tolterodine tartrate) (by Pharmacia & Upjohn), Approved December 2000
For the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency

Gelnique (oxybutynin chloride) (by Watson Pharmaceuticals), Approved January 2009
For the treatment of overactive bladder

Mesnex (by Bristol-Myers Squibb, Baxter Healthcare), Approved March 2002
Oral tablet to inhibit the hemorrhagic cystitis induced by Ifex (ifosfamide)

Oxytrol (oxybutynin transdermal system) (by Watson Pharmaceuticals), Approved March 2003
For the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.

Sanctura (trospium chloride) (by Indevus Pharmaceuticals), Approved May, 2004
For the treatment of overactive bladder with symptoms of urge urinary incontinence

Toviaz (fesoterodine fumarate) (by Pfizer), Approved October 2008
For the treatment of overactive bladder

Vesicare (solifenacin succinate) (by Yamanouchi, GlaxoSmithKline), Approved November, 2004
For the treatment of overactive bladder with symptoms of urge urinary incontinence

Blood Cancer

Blincyto (blinatumomab) (by Amgen), Approved December 2014
For the treatment of Philadelphia chromosome-negative relapsed /refractory B cell precursor acute lymphoblastic leukemia

Blood Clots

Kcentra (Prothrombin Complex Concentrate) (by CSL Behring), Approved May 2013
For the reversal of vitamin K antagonist therapy-induced coagulation factor deficiency

Lovenox (enoxaparin sodium) Injection (by Rhone Poulenc Rorer), Approved February 1998
Treatment for prevention of blood clots following hip-replacement surgery

Tretten (Coagulation Factor XIII A-Subunit [Recombinant]) (by Novo Nordisk), Approved December of 2013
For the treatment of congenital factor XIII (FXIII) A-subunit deficiency

Warfarin Sodium tablets (by Barr Laboratories), Approved March 1997
Generic equivalent of Coumadin

Xarelto (rivaroxaban) (by Bayer), Approved July 2011
For the prophylaxis of deep vein thrombosis during knee or hip replacement surgery

Xarelto (rivaroxaban) (by Janssen Pharmaceuticals), Approved November 2011
For the reduction in the risk of stroke and systemic embolism resulting from atrial fibrillation

Blood Transfusions

Ferriprox (deferiprone) (by Apotex), Approved October 2011
For the treatment of transfusional iron overload due to thalassemia

Kcentra (Prothrombin Complex Concentrate) (by CSL Behring), Approved May 2013
For the reversal of vitamin K antagonist therapy-induced coagulation factor deficiency

Bone Diseases

Elelyso (taliglucerase alfa) (by Pfizer), Approved May 2012
For the treatment of Gaucher disease

Strensiq (asfotase alfa) (by Alexion), Approved October 2015
For the treatment of hypophosphatasia

Bone Metastases

Aredia (pamidronate disodium for injection) (by Chiron), Approved August 1996
Treatment for osteolytic bone metastases of breast cancer

Xgeva (denosumab) (by Amgen), Approved November 2010
For the prevention of skeletal-related events in patients with bone metastases from solid tumors

Xofigo (radium Ra 223 dichloride) (by Bayer Healthcare Pharmaceuticals), Approved May 2013
For the treatment of prostate cancer with bone metastases

Zometa (zoledronic acid) (by Novartis), Approved February 2002
For the treatment of multiple myeloma and bone metastases from solid tumors

Bone Neoplasm

Xgeva (denosumab) (by Amgen), Approved June 2013
For the treatment of giant cell tumor of bone

Xgeva (denosumab) (by Amgen), Approved November 2010
For the prevention of skeletal-related events in patients with bone metastases from solid tumors

Bowel Dysfunction

Gattex (teduglutide) (by NPS Pharmaceuticals), Approved December 2012
For the treatment of short bowel syndrome

Brain Cancer

Avastin (bevacizumab) (by Genentech), Approved May 2009
For the treatment of recurrent glioblastoma in adults

Gliadel Wafer (polifeprosan 20 with carmustine implant) (by Rhone-Poulenc Rorer, Guilford Pharmaceuticals), Approved February 1997
Treatment for brain cancer

Breast Cancer

Afinitor (everolimus) (by Novartis), Approved April 2012
For the treatment of renal angiomyolipoma associated with tuberous sclerosis complex

Afinitor (everolimus) (by Novartis), Approved July 2012
For the treatment of hormone receptor-positive, HER2-negative breast cancer

Afinitor (everolimus) (by Novartis), Approved March 2009
For the treatment of renal cell carcinoma

Afinitor (everolimus) (by Novartis), Approved May 2011
For the treatment of advanced pancreatic neuroendocrine tumors

Aredia (pamidronate disodium for injection) (by Chiron), Approved August 1996
Treatment for osteolytic bone metastases of breast cancer

Arimidex (anastrozole) (by AstraZeneca), Approved January 1996
Treatment for advanced breast cancer in postmenopausal women

Aromasin Tablets (by Pharmacia & Upjohn), October 21, 1999
Exemestane Tablets, 25 mg

Ellence (by Pharmacia & Upjohn), Approved September 1999
epirubicin hydrochloride

Evista (raloxifene hydrochloride) (by Eli Lilly), Approved September 2007
For the treatment/prevention of osteoporosis and reduction of breast cancer risk in postmenopausal women

Faslodex (fulvestrant) (by AstraZeneca), Approved April 2002
For the treatment of hormone receptor positive metastatic breast cancer

Femara (letrozole) (by Novartis), Approved January 2001
First-line treatment of postmenopausal women with locally advanced or metastatic breast cancer

Femara (letrozole) (by Novartis), Approved July 1997
Treatment for breast cancer

Halaven (eribulin mesylate) (by Eisai), Approved November 2010
For the treatment of metastatic breast cancer

Herceptin (by Genentech), Approved October 1998
Treatment for metastatic breast cancer

Ibrance (palbociclib) (by Pfizer), Approved February 2015
For the treatment of ER-positive, HER2-negative breast cancer

Inform HER-2/neu breast cancer test (by Oncor), Approved January 1998
Treatment for breast cancer prediction

Ixempra (ixabepilone) (by Bristol-Myers Squibb), Approved October 2007
For the treatment of breast cancer

Kadcyla (ado-trastuzumab emtansine) (by Genentech), Approved February 2013
For the treatment of HER2-positive metastatic breast cancer

Kisqali (ribociclib) (by Novartis), Approved March 2017
For the treatment of breast cancer

Perjeta (pertuzumab) (by Genentech), Approved June 2012
For the first-line treatment of HER2+ metastatic breast cancer

Talzenna (talazoparib) (by Pfizer), Approved October 2018
For the treatment of deleterious germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer

Taxotere (Docetaxel) (by Rhone Poulenc Rorer), Approved May 1996
Treatment for locally advanced or metastatic breast cancer

Tykerb (lapatinib) (by GlaxoSmithKline), Approved March 2007
For the treatment of breast cancer

Verzenio (abemaciclib) (by Eli Lilly), Approved September 2017
For the treatment of HR+, HER2- breast cancer

Xeloda (by Roche), Approved April 1998
Treatment for advanced breast cancer tumors

Breast Cancer - HER2 Positive

Nerlynx (neratinib) (by Puma Biotech), Approved July 2017
For the treatment of HER2 breast cancer

Bronchitis

Augmentin (amoxicillin/clavulanate) (by SmithKline Beecham), Approved February 1996
Treatment for infections involving drug-resistant bacteria

Avelox I.V. (moxifloxacin hydrochloride) (by Bayer), Approved November 2001
Injectable antibacterial agent for adults with susceptible strains of bacterial infections

Ceftin (cefuroxime axetil) (by GlaxoSmithKline), Approved September 1997
Treatment of secondary bacterial infections of acute bronchitis

Tudorza Pressair (aclidinium bromide inhalation powder) (by Forest Laboratories), Approved July 2012
For the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease

Burns and Burn Infections

Dermagraft-TC (by Advanced Tissue Sciences), Approved October 1997
Treatment for partial-thickness and severe burns

Sulfamylon (by Mylan Laboratories), Approved June 1998
Treatment used to control bacterial infections on excised burn wounds

Cancer Pain

Abstral (fentanyl sublingual tablets) (by ProStrakan), Approved January 2011
For the treatment of breakthrough cancer pain in opioid-tolerant patients

Lazanda (fentanyl citrate) nasal spray (by Archimedes), Approved June 2011
For the management of breakthrough cancer pain

Onsolis (fentanyl buccal) (by BioDelivery Sciences), Approved July 2009
For the management of breakthrough cancer pain

Quadramet (Samarium Sm 153 Lexidronam Injection) (by DuPont Merck Pharmaceutical Company), Approved March 1997
Treatment for pain associated with bone cancer

Subsys (fentanyl sublingual spray) (by Insys Therapeutics), Approved January of 2012
For the treatment of breakthrough cancer pain

Cancer Prevention

Cervarix [Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant (by GlaxoSmithKline), Approved October 2009
For the prevention of cervical cancer and cervical intraepithelial neoplasia caused by HPV types 16 and 18

Inform HER-2/neu breast cancer test (by Oncor), Approved January 1998
Treatment for breast cancer prediction

Self-examination breast pad (by Inventive Products), Approved on December 22, 1995
Self-examination breast pad

Cancer/Tumors

Subsys (fentanyl sublingual spray) (by Insys Therapeutics), Approved January of 2012
For the treatment of breakthrough cancer pain

Candidemia/Candidiasis

Oravig (miconazole) (by Strativa Pharmaceuticals), Approved April 2010
oropharyngeal candidiasis

Canker Sores

Aphthasol (by Block Drug Company), Approved December 1997
Treatment for canker sores

Apthasol (Amlexanox) (by Access Pharmaceuticals), Approved May 1996
Treatment for canker sores

Carrington patch (by Carrington Laboratories), Approved May 1996
Treatment for canker sores

Cardiac Ischemia

ReoPro (by Centocor Ortho Biotech), Approved November 1997
Treatment for cardiac ischemic complications

Zontivity (vorapaxar) (by Merck), Approved May 2014
For the reduction of thrombotic cardiovascular events

Cardiovascular Abnormalities

Invokana (canagliflozin) (by Janssen Pharmaceuticals), Approved April 2013
For the treatment of type II diabetes and to reduce the risk of cardiovascular events in type II diabetics

Kynamro (mipomersen sodium) (by Genzyme), Approved January 2013
For the treatment of homozygous familial hypercholesterolemia

Praluent (alirocumab) (by Sanofi Aventis), Approved July 2015
For the treatment of heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease

Repatha (evolocumab) (by Amgen), Approved August 2015
For the treatment of high cholesterol

Yosprala (aspirin and omeprazole) (by Aralez Pharmaceuticals), Approved September 2016
For the prevention of cardiovascular and cerebrovascular events

Cataracts

Omidria (phenylephrine and ketorolac injection) (by Omeros), Approved June 2014
For use during eye surgery to prevent intraoperative miosis and reduce post-operative pain

Cerebral Ischemia

Yosprala (aspirin and omeprazole) (by Aralez Pharmaceuticals), Approved September 2016
For the prevention of cardiovascular and cerebrovascular events

Cervical Cancer

Avastin (bevacizumab) (by Genentech), Approved August 2014
For the treatment of persistent, recurrent, or metastatic cervical cancer

Cervarix [Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant (by GlaxoSmithKline), Approved October 2009
For the prevention of cervical cancer and cervical intraepithelial neoplasia caused by HPV types 16 and 18

Keytruda (pembrolizumab) (by Merck), Approved June 2018
For the treatment of recurrent or metastatic cervical cancer

Chemotherapy

Varubi (rolapitant) (by Tesaro), Approved September 2015
For the prevention of delayed nausea and vomiting associated with chemotherapy

Chickenpox (Varicella Zoster Infection)

VariZIG, Varicella Zoster Immune Globulin (Human) (by Cangene), Approved January 2013
For the post-exposure prophylaxis of varicella zoster (chickenpox)

Chronic Bronchitis

Biaxin XL (clarithromycin extended-release tablets) (by Abbott Laboratories), Approved March 2000
For Acute Bacterial Exacerbation of Chronic Bronchitis (AECB) and Acute Maxillary Sinusitis

Cedax (ceftibuten) (by Schering-Plough), Approved December 1995
Treatment for chronic bronchitis, acute bacterial otitis media, pharyngitis/tonsillitis

Raxar (grepafloxacin) (by GlaxoSmithKline), Approved November 1997
Treatment for chronic bronchitis

Zagam (sparfloxacin) tablets (by Rhone Poulenc Rorer), Approved January 1997
Treatment for community-acquired pneumonia (CAP) and chronic bronchitis

Chronic Diarrhea

Aemcolo (rifamycin) (by Aries Pharmaceuticals), Approved November 2018
For the treatment of traveler's diarrhea

Mytesi (crofelemer) (by Napo Pharmaceuticals), Approved December 2012
For the treatment of non-infectious diarrhea in adults with HIV/AIDS

Viberzi (eluxadoline) (by Actavis), Approved May 2015
For the treatment of irritable bowel syndrome with diarrhea

Xermelo (telotristat ethyl) (by Lexicon Pharmaceuticals), Approved February 2017
For the treatment of carcinoid syndrome diarrhea

Xifaxan (rifaximin) (by Salix Pharmaceuticals), Approved May 2015
For the treatment of irritable bowel syndrome with diarrhea

Chronic Lymphocytic Leukemia

Arzerra (ofatumumab) (by GlaxoSmithKline), Approved October 2009
For the treatment of chronic lymphocytic leukemia

Copiktra (duvelisib) (by Verastem), Approved September 2018
For the treatment of chronic lymphocytic leukemia, small lymphocytic lymphoma or follicular lymphoma

Elliotts B Solution (buffered intrathecal electrolyte/dextrose injection) (by Orphan Medical), Approved October 1996
Treatment of meningeal leukemia or lymphocytic lymphoma

Gazyva (obinutuzumab) (by Genentech), Approved October of 2013
For the treatment of previously untreated chronic lymphocytic leukemia

Imbruvica (ibrutinib) (by Pharmacyclics), Approved February 2014
For the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma

Imbruvica (ibrutinib) (by Pharmacyclics), Approved November of 2013
For the treatment of mantle cell lymphoma

Lumoxiti (moxetumomab pasudotox-tdf) (by AstraZeneca), Approved September 2018
For the treatment of relapsed or refractory hairy cell leukemia

Treanda (bendamustine hydrochloride) (by Cephalon), Approved October 2008
For the treatment of Chronic lymphocytic leukemia and B-cell non-Hodgkin’s lymphoma

Venclexta (venetoclax) (by AbbVie), Approved April 2016
For the treatment of chronic lymphocytic leukemia with 17p deletion

Zydelig (idelalisib) (by Gilead), Approved July 2014
For the treatment of relapsed CLL, follicular B-cell NHL and small lymphocytic lymphoma

Chronic Myeloid Leukemia

Bosulif (bosutinib) (by Pfizer), Approved September 2012
For the treatment of Ph+ chronic myelogenous leukemia

Gleevec (imatinib mesylate) (by Novartis), Approved May 2001
Oral therapy for the treatment of chronic myeloid leukemia

Iclusig (ponatinib) (by Ariad Pharmaceuticals), Approved December 2012
For the treatment of chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia

Sprycel (dasatinib) (by Bristol-Myers Squibb), Approved June 2006
For the treatment of imatinib-resistant chronic myeloid leukemia

Synribo (omacetaxine mepesuccinate) (by Teva Pharmaceutical), Approved October 2012
For the treatment of chronic or accelerated phase chronic myeloid leukemia

Chronic Obstructive Lung Disease

Incruse Ellipta (umeclidinium inhalation powder) (by GlaxoSmithKline), Approved May 2014
For the treatment of chronic obstructive pulmonary disease

Tudorza Pressair (aclidinium bromide inhalation powder) (by Forest Laboratories), Approved July 2012
For the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease

Yupelri (revefenacin) (by Theravance Biopharma), Approved November 2018
For the maintenance treatment of chronic obstructive pulmonary disease

Chronic Pain

Anexsia (by Mallinckrodt Group), Approved August 1996
Treatment for chronic pain

Avinza (morphine sulfate) (by Elan Pharmaceuticals), Approved March 2002
Extended release capsule for the relief of pain requiring continuous, around-the-clock therapy

Belbuca (buprenorphine) (by Endo Pharmaceuticals), Approved October 2015
For the management of severe pain

Butrans (buprenorphine) Transdermal System (by Purdue Pharma), Approved July 2010
moderate to severe chronic pain

Kadian (by Purepac Pharmaceutical), Approved July 1996
Treatment for chronic moderate to severe pain

Movantik (naloxegol) (by AstraZeneca), Approved September 2014
For the treatment of opiod-induced constipation in adults with chronic non-cancer pain

Targiniq ER (oxycodone hydrochloride + naloxone hydrochloride) extended-release tablets (by Purdue Pharma), Approved July 2014
For the management of severe chronic pain

Troxyca ER (oxycodone + naltrexone) (by Pfizer), Approved August 2016
For the management of severe pain

UltraJect (by Mallinckrodt Group), Approved August 1996
Treatment for chronic pain

Vivlodex (meloxicam) (by Iroko Pharmaceuticals), Approved October 2015
For the management of osteoarthritis pain

Clostridium Difficile-Associated Diarrhea

Dificid (fidaxomicin) (by Optimer Pharmaceuticals), Approved May 2011
For the treatment of Clostridium difficile-associated diarrhea

Zinplava (bezlotoxumab) (by Merck), Approved October 2016
For the treatment of recurrent Clostridium difficile infection in patients receiving antibacterial treatment

Cold Sores (Herpes Labialis Infections)

Sitavig (acyclovir) buccal tablets (by BioAlliance Pharma), Approved April 2013
For the treatment of recurrent herpes labialis in adults

Colorectal Cancer

Avastin (bevacizumab) (by Genentech), Approved February 2004
For the treatment of metastatic carcinoma of the colon or rectum

Campostar (by Pharmacia & Upjohn), Approved June 1996
Treatment for metastatic colorectal cancer

CEA-Scan (by Immunomedics), Approved April 1996
Diagnostic imaging product for colorectal cancer

Erbitux (cetuximab) (by Imclone, Bristol-Myers Squibb), Approved February 2004
For the treatment of EGFR-expressing, metastatic colorectal cancer

Keytruda (pembrolizumab) (by Merck), Approved May 2017
For the treatment of microsatellite instability-high or mismatch repair deficient solid tumors and colorectal cancer

Lonsurf (trifluridine and tipiracil) (by Taiho Oncology), Approved September 2015
For the treatment of metastatic colorectal cancer

Opdivo (nivolumab) (by Bristol-Myers Squibb), Approved August 2018
For the treatment of MSI-H or dMMR metastatic colorectal cancer

Stivarga (regorafenib) (by Bayer HealthCare Pharmaceuticals), Approved September 2012
For the treatment of previously treated patients with metastatic colorectal cancer

Vectibix (panitumumab) (by Amgen), Approved September 2006
For the treatment of colorectal cancer

Zaltrap (ziv-aflibercept) (by Sanofi-aventis), Approved August 2012
For the treatment of metastatic colorectal cancer

Common Cold

Atrovent (ipratropium bromide) (by Boehringer Ingelheim), Approved January 1996
Treatment for runny nose due to allergies and the common cold

Children's Advil (pediatric ibuprofen) (by Whitehall-Robins Healthcare), Approved July 1996
Treatment of fever and minor aches and pains

Children's Motrin Cold (by McNeil Consumer Products), Approved August 2000
For temporary relief of the common cold

Tavist (clemastine fumarate) (by Novartis), Approved March 2001
Oral tablet for temporary relief of symptoms associated with hay fever, allergic rhinitis, and the common cold

Tavist (clemastine fumarate) (by Sandoz Pharmaceuticals), Approved November 1996
Treatment for cold symptoms

Conjunctivitis, Bacterial

Grastek (Timothy Grass Pollen Allergen Extract) (by Merck), Approved April 2014
For the treatment of grass pollen-induced allergic rhinitis

Ragwitek (Short Ragweed Pollen Allergen Extract) (by Merck), Approved April 2014
For the treatment of short ragweed pollen-induced allergic rhinitis

Zymaxid (gatifloxacin ophthalmic solution) (by Allergan), Approved May 2010
For the treatment of bacterial conjunctivitis

Constipation

Linzess (linaclotide) (by Forest Labs and Ironwood Pharmaceuticals), Approved August 2012
For the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation

Motegrity (prucalopride) (by Shire Pharmaceuticals), Approved December 2018
For the treatment of chronic idiopathic constipation

Movantik (naloxegol) (by AstraZeneca), Approved September 2014
For the treatment of opiod-induced constipation in adults with chronic non-cancer pain

Symproic (naldemedine) (by Shionogi), Approved March 2017
For the treatment of opioid-induced constipation

Trulance (plecanatide) (by Synergy Pharmaceuticals), Approved January 2017
For the treatment of adults with chronic idiopathic constipation

Contraception

Alesse (100 mcg levonorgestrel/20 mcg ethinyl estradiol tablets) (by Wyeth), Approved April 1997
Treatment for the prevention of pregnancy

Annovera (segesterone acetate andethinylestradiolvaginal system) (by TherapeuticsMD), Approved August 2018
For the prevention of pregnancy

ella (ulipristal acetate) (by HRA Pharma), Approved August 2010
For the emergency prevention of contraception

Estrostep (norethindrone acetate and ethinyl estradiol) (by Warner-Lambert), Approved March 1997
Treatment for oral contraception

Estrostep (norethindrone acetate and ethinyl estradiol) (by Parke-Davis), Approved October 1996
Treatment for birth control

Lo Minastrin, (norethindrone acetate, ethinyl estradiol, ferrous fumarate) (by Warner Chilcott), Approved July 2013
For the prevention of pregnancy

Mircette (by Organon), Approved April 1998
Oral contraceptive

Mirena (levonorgestrel-releasing intrauterine system) (by Berlex Laboratories), Approved December 2000
Hormone-releasing system for intrauterine contraception

Natazia (estradiol valerate + dienogest) (by Bayer), Approved May 2010
For the prevention of contraception

NuvaRing (by Organon), Approved October 2001
Monthly vaginal ring for birth control

Ortho Evra (by Ortho-McNeil Pharmaceutical), Approved November 2001
Transdermal patch for contraception

Quartette (levonorgestrel/ethinyl estradiol and ethinyl estradiol) (by Teva Pharmaceutical), Approved April 2013
For the prevention of conception

Seasonale, Lo Seasonale, Seasonique (ethinylestradiol + levonorgestrel) (by Duramed Pharmaceuticals), Approved September 2003
For the prevention of contraception

Trivora-21 and Trivora-28 (by Watson Pharmaceuticals), Approved December 1997
Generic equivalents of levonorgestrel and ethinyl estradiol

Yasmin (drospirenone/ethinyl estradiol) (by Berlex Laboratories), Approved May 2001
Oral contraceptive

COPD (Chronic Obstructive Pulmonary Disease)

Advair (fluticasone propionate and salmeterol) (by GlaxoSmithKline), Approved August 2000
For the treatment of asthma and chronic obstructive pulmonary disease

Anoro Ellipta (umeclidinium and vilanterol inhalation powder) (by GlaxoSmithKline), Approved December of 2013
For the maintenance treatment of chronic obstructive pulmonary disease

Arcapta (indacaterol maleate inhalation powder) (by Novartis), Approved July 2011
For the treatment of airflow obstruction resulting from chronic obstructive pulmonary disease

Bevespi Aerosphere (glycopyrrolate and formoterol fumarate) (by AstraZeneca), Approved April 2016
For the treatment of chronic obstructive pulmonary disease

Breo Ellipta (fluticasone furoate and vilanterol inhalation powder) (by GlaxoSmithKline), Approved May 2013
For the treatment of chronic obstructive pulmonary disease

Daliresp (roflumilast) (by Forest Pharmaceuticals), Approved February 2011
For the treatment of chronic obstructive pulmonary disease

DuoNeb (albuterol sulfate and ipratropium bromide) (by Dey Laboratories), Approved March 2001
For the treatment of bronchospasm associated with COPD

Foradil Aerolizer (formoterol fumarate inhalation powder) (by Novartis), Approved February 2001 (asthma, bronchospasm); September 2001 (COPD)
Bronchodilator for COPD, asthma and bronchospasm

Incruse Ellipta (umeclidinium inhalation powder) (by GlaxoSmithKline), Approved May 2014
For the treatment of chronic obstructive pulmonary disease

Spiriva HandiHaler (tiotropium bromide) (by Boehringer Ingelheim), Approved February 2004
For the treatment of bronchospasm associated with chronic obstructive pulmonary disease

Stiolto Respimat (tiotropium bromide and olodaterol) (by Boehringer Ingelheim), Approved May 2015
For the maintenance of chronic obstructive pulmonary disease

Striverdi Respimat (olodaterol) (by Boehringer Ingelheim), Approved July 2014
For the treatment of chronic obstructive pulmonary disease

Tudorza Pressair (aclidinium bromide inhalation powder) (by Forest Laboratories), Approved July 2012
For the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease

Utibron Neohaler (indacaterol and glycopyrrolate) (by Novartis), Approved October 2015
For the long term, maintenance treatment of airflow obstruction in patients with COPD

Yupelri (revefenacin) (by Theravance Biopharma), Approved November 2018
For the maintenance treatment of chronic obstructive pulmonary disease

Coronary Artery Disease

Kengreal (cangrelor) (by The Medicines Company), Approved June 2015
For reducing periprocedural thrombotic events

Crohn's Disease

Cimzia (certolizumab pegol) (by UCB), Approved April 2008
For the treatment of Crohn’s disease

Entocort EC (budesonide) (by AstraZeneca), Approved October 2001
Capsules for the treatment of mild-to-moderate, active Crohn's disease

Entyvio (vedolizumab) (by Millenium Pharmaceuticals), Approved May of 2014
For the treatment of adults with ulcerative colitis and Crohn's disease

Stelara (ustekinumab) (by Janssen Biotech), Approved September 2009
For the treatment of plaque psoriasis, psoriatic arthritis and Crohn's disease

Tysabri (natalizumab) (by Biogen IDEC), Approved January 2008
For the maintenance treatment of moderate to severe Crohn’s disease

Cushing's Disease

Korlym (mifepristone) (by Corcept Therapeutics), Approved February 2012
For the control of hyperglycemia in adults with endogenous Cushing’s syndrome

Signifor (pasireotide diaspartate) (by Novartis), Approved December of 2012
For the treatment of Cushing's disease

Cutaneous T-Cell Lymphoma

Istodax (romidepsin) (by Gloucester Pharmaceuticals), Approved November 2009
For the treatment of cutaneous T-cell lymphoma

Valchlor (mechlorethamine) gel (by Ceptaris Therapeutics), Approved August 2013
For the treatment of Stage IA/IB mycosisfungoides-type cutaneous T-cell lymphoma

Cystic Fibrosis

Cayston (aztreonam for inhalation solution) (by Gilead), Approved February 2010
For the treatment of cystic fibrosis patients with Pseudomonas aeruginosa

Kalydeco (ivacaftor) (by Vertex Pharmaceuticals), Approved January of 2012
For the treatment of cystic fibrosis with the G551D mutation in the CFTR gene

Orkambi (lumacaftor and ivacaftor) (by Vertex Pharmaceuticals), Approved July 2015
For the treatment of cystic fibrosis

Pulmozyme (dornase alfa) (by Genentech), Approved December 1996
Treatment for cystic fibrosis patients with advanced disease

Pulmozyme (dornase alfa) (by Genentech), Approved March 1998
Treatment for cystic fibrosis

Symdeko (tezacaftor/ivacaftor) (by Vertex), Approved February 2018
For the treatment of cystic fibrosis

Tobi (by PathoGenesis), Approved December 1997
Treatment for cystic fibrosis

Ultresa (pancrelipase) delayed-release capsules (by Aptalis Pharma), Approved March 2012
For the treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions

Zenpep (pancrelipase) (by Eurand), Approved August 2009
For the treatment of pancreatic insufficiency due to cystic fibrosis or other conditions

Cytomegalovirus (CMV) Retinitis

Oral Cytovene (by Roche), Approved December 1996
Treatment for the prevention of cytomegalovirus (CMV)

Vistide (cidofovir) (by Gilead), Approved June 1996
Treatment for cytomegalovirus (CMV) retinitis

Vitrasert Implant (by Chiron), Approved March 1996
Drug delivery system for the treatment of cytomegalovirus

Vitravene Injection (by Isis Pharmaceuticals), Approved August 1998
Treatment for CMV in AIDS patients

Cytomegalovirus Infections

Prevymis (letermovir) (by Merck), Approved November 2017
For the prevention of cytomegalovirus following allogenic hematopoietic stem cell transplant

Deep Vein Thrombosis

Savaysa (edoxaban) (by Daiichi Sankyo), Approved January 2015
For the treatment of deep vein thrombosis, pulmonary embolism and risk of stroke and embolism due to atrial fibrillation

Dementia

Namzaric (memantine hydrochloride extended-release + donepezil hydrochloride) (by Forest Laboratories), Approved December 2014
For the treatment of moderate to severe dementia of the Alzheimer's type

Depression

Brintellix (vortioxetine) (by Takeda Pharmaceuticals USA), Approved October 2013
For the treatment of Major Depressive Disorder

Celexa (by Forest Laboratories), Approved July 1998
Treatment for depression

Clomipramine hydrochloride (by Mylan Laboratories), Approved April 1998
Generic equivalent of Anafranil

Cymbalta (duloxetine) (by Eli Lilly), Approved August 2004
For the treatment of major depressive disorder

Effexor XR (venlafaxin HCI) (by Wyeth), Approved October 1997
Treatment of depression

Fetzima (levomilnacipran) (by Forest Laboratories), Approved July 2013
For the treatment of major depressive disorder

Lithobid (Lithium Carbonate) (by Solvay Pharmaceuticals), Approved January 1996
Treatment for manic depression

Marplan Tablets (by Roche), Approved August 1998
Treatment of Depression

Paxil CR (paroxetine hydrochloride) (by GlaxoSmithKline), Approved February 2002
Oral tablet for the treatment of depression and panic disorder

Prozac Weekly (fluoxetine HCl) (by Eli Lilly), Approved February 2001
For the treatment of depression

Remeron (Mirtazapine) (by Organon), Approved June 1996
Treatment for depression

Remeron SolTab (mirtazapine) (by Organon), Approved January 2001
Orally disintegrating tablet for the treatment of depression

Rexulti (brexpiprazole) (by Otsuka), Approved July 2015
For the treatment of depression and schizophrenia

Trazadone 150mg (by Teva Pharmaceutical), Approved May 1997
Generic equivalent of Desyrel 7

Depression (Major/Severe)

Lexapro (escitalopram oxalate) (by Forest Laboratories), Approved August 2002
An orally administered selective serotonin reuptake inhibitor useful for the treatment for major depressive disorder

Oleptro (trazodone hydrochloride) (by Labopharm), Approved February 2010
For the treatment of major depressive disorder

Rexulti (brexpiprazole) (by Otsuka), Approved July 2015
For the treatment of depression and schizophrenia

Viibryd (vilazodone hydrochloride) (by Clinical Data), Approved January 2011
For the treatment of major depressive disorder

Dermatitis, Atopic

Dupixent (dupilumab) (by Regeneron Pharmaceuticals), Approved March 2017
For the treatment of atopic dermatitis

Eucrisa (crisaborole) ointment (by Pfizer), Approved December 2016
For the treatment of atopic dermatitis

Diabetes Mellitus Types I and II

Afrezza (insulin human) Inhalation Powder (by Mannkind), Approved June 2014
For the treatment of diabetes mellitus

Glipizide Tablets (by Duramed Pharmaceuticals), Approved September 1997
Treatment for diabetes

Glucagon (by Eli Lilly), Approved October 1998
Treatment for severe hypoglycemia associated with diabetes.

Glyburide Tablets (by Mylan Laboratories), Approved July 1998.
Treatment for Diabetes Mellitus (Type II)

Humalog (insulin lispro) (by Eli Lilly), Approved June 1996
Treatment for type I and type II diabetes

Lantus (insulin glargine [rDNA origin] injection) (by Sanofi-aventis), Approved April 2000
For the treatment of type I and type II diabetes mellitus in adults and pediatrics

Lantus (insulin glargine [rDNA origin] injection) (by Sanofi-aventis), Approved April 2000
For adults and children w/Type 1 diabetes, or adults w/Type 2 diabetes requiring basal insulin to control hyperglycemia

NovoLog (insulin aspart) (by Novo Nordisk), Approved June 2000
An insulin analogue for the treatment of diabetes mellitus.

Novolog Mix 70/30 (by Novo Nordisk), Approved November 2001
Subcutaneous injection for the control of hyperglycemia, associated with type 1 and 2 diabetes

Symlin (pramlintide) (by Amylin Pharmaceuticals), Approved March 2005
For the treatment of type I and type II diabetes

Tresiba (insulin degludec injection) (by Novo Nordisk), Approved September 2015
For glycemic control in adults with diabetes mellitus

Diabetes Mellitus, Type 2

ACTOplus met (pioglitazone hydrochloride and metformin hydrochloride) (by Takeda), Approved August of 2005
For the treatment of type 2 diabetes

Adlyxin (lixisenatide) (by Sanofi Aventis), Approved July 2016
For the treatment of type II diabetes

Amaryl (Glimepiride) (by Hoechst Marion Roussel), Approved December 1995
Treatment for type II diabetes

Avandamet (rosiglitazone maleate and metformin HCl) (by GlaxoSmithKline), Approved October 2002
For improvement of glycemic control in type 2 diabetes patients

Bydureon (exenatide extended-release for injectable suspension) (by Amylin), Approved January 2012
For the improvement of glycemic control in adults with type II diabetes mellitus

Byetta (exenatide) (by Amylin/Eli Lilly), Approved April, 2005
For the adjunctive treatment of Type 2 diabetes mellitus

Cycloset, bromocriptine mesylate (by VeroScience), Approved May 2009
For the treatment of type 2 diabetes mellitus

Farxiga (dapagliflozin) (by Bristol-Myers Squibb), January of 2014
For the treatment of type II diabetes

Glyset (miglitol) (by Bayer), Approved December 1996
Treatment for Type II (non-insulin-dependent) diabetes mellitus

Invokana (canagliflozin) (by Janssen Pharmaceuticals), Approved April 2013
For the treatment of type II diabetes and to reduce the risk of cardiovascular events in type II diabetics

Januvia (sitagliptin phosphate) (by Merck), Approved October 2006
For the treatment of type II diabetes

Jardiance (empagliflozin) (by Boehringer Ingelheim), Approved August 2014
For the treatment of type II diabetes

Jentadueto (linagliptin plus metformin hydrochloride) (by Eli Lilly), Approved February 2012
For the treatment of type II diabetes

Juvisync (sitagliptin and simvastatin) (by Merck), Approved October 2011
For the treatment of type II diabetes

Metaglip (glipizide/metformin HCl) (by Bristol-Myers Squibb), Approved October 2002
Oral tablets for the treatment of type 2 diabetes.

Nesina (alogliptin) (by Takeda), Approved January 2013
For the treatment of type II diabetes mellitus

Onglyza (saxagliptin) (by Bristol-Myers Squibb), Approved July 2009
For the treatment of type 2 diabetes mellitus

Ozempic (semaglutide) (by Novo Nordisk), Approved December 2017
For the treatment of type II diabetes

Prandin (by Novo Nordisk), Approved December 1997
Treatment for Type II diabetes

Precose (acarbose) (by Bayer), Approved September 6, 1995
Treatment for non-insulin-dependent diabetes mellitus

Qtern (dapagliflozin and saxagliptin) (by AstraZeneca), Approved February 2017
For the treatment of inadequately controlled type II diabetes

Soliqua 100/33 (insulin glargine and lixisenatide injection) (by Sanofi Aventis), Approved November 2016
For the treatment of inadequately controlled type II diabetes

Steglatro (ertugliflozin) (by Merck), Approved December 2017
For the treatment of type 2 diabetes mellitus

Synjardy (empagliflozin and metformin hydrochloride) (by Boehringer Ingelheim), Approved August 2015
For the treatment of type II diabetes

Tanzeum (albiglutide) (by GlaxoSmithKline), Approved April 2014
For the treatment of type II diabetes mellitus

Tradjenta (linagliptin) (by Boehringer Ingelheim), Approved May 2011
For the treatment of type II diabetes

Trulicity (dulaglutide) (by Eli Lilly), Approved September 2014
To improve glycemic control in type II diabetics

Victoza (liraglutide) (by Novo Nordisk), Approved January 2010
For the treatment of type 2 diabetes mellitus

Welchol (colesevelam hydrochloride) (by Daiichi Sankyo), Approved January 2008
For the improvement of glycemic control in adults with type 2 diabetes mellitus

Xigduo XR (dapagliflozin + metformin hydrochloride) (by AstraZeneca), Approved October 2014
For glycemic control in adults with type II diabetes

Xultophy 100/3.6 (insulin degludec and liraglutide injection) (by Novo Nordisk), Approved November 2016
For the treatment of inadequately controlled type II diabetes

Diabetic Foot Ulcers

REGRANEX (becaplermin) Gel (by RW Johnson), Approved December 1997
Treatment for diabetic foot ulcers

Diabetic Gastroparesis

Metozolv ODT (metoclopramide hydrochloride) (by Salix Pharmaceuticals), Approved September of 2009
For the treatment of gastroesophageal reflux and diabetic gastroparesis

Diabetic Macular Edema

Eylea (aflibercept) (by Regeneron Pharmaceuticals), Approved July 2014
For the treatment of diabetic macular edema

Eylea (aflibercept) (by Regeneron Pharmaceuticals), Approved March 2015
For the treatment of diabetic retinopathy in patients with diabetic macular edema

Lucentis (ranibizumab injection) (by Genentech), Approved August 2012
For the treatment of diabetic macular edema

Diabetic Retinopathy

Eylea (aflibercept) (by Regeneron Pharmaceuticals), Approved March 2015
For the treatment of diabetic retinopathy in patients with diabetic macular edema

Diet and Nutrition

Nesina (alogliptin) (by Takeda), Approved January 2013
For the treatment of type II diabetes mellitus

Dizzy/Fainting Spells

Northera (droxidopa) (by Chelsea Therapeutics), Approved February 2014
For the treatment of neurogenic orthostatic hypotension

Dravet Syndrome

Diacomit (stiripentol) (by Biocodex), Approved August 2018
For the treatment of seizures associated with Dravet syndrome

Epidiolex (cannabidiol) (by GW Pharmaceuticals), Approved June 2018
For the treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome

Dry Eye Disease

Xiidra (lifitegrast) (by Shire), Approved July 2016
For the treatment of dry eye disease

Duodenal Ulcers

Prevpac (by TAP Pharmaceuticals), Approved December 1997
Treatment for duodenal ulcers

Prilosec (omeprazole)/Biaxin (clarithromycin) Combination Therapy (by Astra Merck, Abbott Laboratories), Approved April 1996
Treatment for duodenal ulcers

Dupuytren's Disease

Xiaflex (collagenase clostridium histolyticum) (by Auxilium Pharmaceuticals), Approved February 2010
For the treatment of Dupuytren’s contracture

Dyskinesias

Gocovri (amantadine) (by Adamas Pharmaceuticals), Approved August 2017
For the treatment of Parkinson's disease dyskinesia

Dystonias

Xeomin (incobotulinumtoxinA) (by Merz Pharmaceutical), Approved July 2010
For the treatment of cervical dystonia and blepharospasm

Ear Infections

Cedax (ceftibuten) (by Schering-Plough), Approved December 1995
Treatment for chronic bronchitis, acute bacterial otitis media, pharyngitis/tonsillitis

Floxin otic (by Daiichi Sankyo), Approved December 1997
Treatment for otitis media

Xtoro (finafloxacin otic suspension) 0.3% (by Alcon), Approved December 2014
For the treatment of acute otitis externa

Ear Infections (Pediatric)

Otiprio (ciprofloxacin otic suspension) (by Otonomy), Approved December 2015
For the treatment of pediatrics with bilateral otitis media with effusion undergoing tympanostomy tube placement

Rocephin (by Roche), Approved January 1998
Treatment for pediatric otitis media

Effects of Chemotherapy

Akynzeo (netupitant and palonosetron) (by Helsinn), Approved October 2014
For the prevention of chemotherapy-induced nausea and vomiting

Sustol (granisetron) (by Heron Therapeutics), Approved August 2016
For the prevention of chemotherapy-induced nausea and vomiting

Syndros (dronabinol oral solution) (by Insys Therapeutics), Approved July 2016
For the treatment of anorexia associated with AIDS and nausea and vomiting associated with cancer chemotherapy

Varubi (rolapitant) (by Tesaro), Approved September 2015
For the prevention of delayed nausea and vomiting associated with chemotherapy

Vistogard (uridine triacetate) (by Wellstat Therapeutics), Approved December 2015
For the emergency treatment of patients with a fluorouracil or capecitabine overdose

Zuplenz (ondansetron oral soluble film) (by Strativa Pharmaceuticals), Approved July 2010
For the prevention of post-operative, chemotherapy and radiotherapy induced nausea and vomiting

Elevated Triglycerides (Hypertriglyceridemia)

Epanova (omega-3-carboxylic acids) (by AstraZeneca), Approved May 2014
For the treatment of severe hypertriglyceridemia

Endometriosis

Orilissa (elagolix) (by AbbVie), Approved July 2018
For the management of moderate to severe pain associated with endometriosis

Epilepsy

Briviact (brivaracetam) (by UCB), Approved February 2016
For the treatment of partial onset seizures related to epilepsy

Carnexiv (carbamazepine) (by Lundbeck), Approved October 2016
replacement therapy when oral administration is not feasible, in adults with seizures

Depakote (divalproex sodium) (by Abbott Laboratories), Approved June 1996
Treatment for epilepsy

Fycompa (perampanel) (by Eisai), Approved October 2012
For the treatment of partial-onset seizures with or without secondarily generalized seizures; tonic-clonic seizures